J0751 Hiv prep, ftc/taf 200/25mg
Also known as: Descovy PrEP, FTC/TAF, emtricitabine/tenofovir alafenamide
Emtricitabine/tenofovir alafenamide oral pre-exposure prophylaxis formulation, supplied as 200 milligram emtricitabine and 25 milligram tenofovir alafenamide per dose for Human Immunodeficiency Virus prevention.
In Plain Language
Newer HIV prevention pill with fewer side effects; Daily HIV prevention medication
Clinical Context
Used for pre-exposure prophylaxis in Human Immunodeficiency Virus-negative individuals at risk of exposure, with improved bone and renal safety profile compared to tenofovir disoproxil fumarate formulation.
RVU Information
CPT J0751 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0751?
CPT J0751 (Hiv prep, ftc/taf 200/25mg) is a J Codes (Drugs) code. Emtricitabine/tenofovir alafenamide oral pre-exposure prophylaxis formulation, supplied as 200 milligram emtricitabine and 25 milligram tenofovir alafenamide per dose for Human Immunodeficiency Virus prevention.
How is J0751 administered?
CPT J0751 is administered by a healthcare provider, typically via injection or infusion. Used for pre-exposure prophylaxis in Human Immunodeficiency Virus-negative individuals at risk of exposure, with improved bone and renal safety profile compared to tenofovir disoproxil fumarate formulation. It is used by Infectious Disease, Public Health, Internal Medicine.
When is CPT J0751 used?
Used for pre-exposure prophylaxis in Human Immunodeficiency Virus-negative individuals at risk of exposure, with improved bone and renal safety profile compared to tenofovir disoproxil fumarate formulation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.